Compare TKC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKC | ABCL |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | Turkey | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.1B |
| IPO Year | 2001 | 2020 |
| Metric | TKC | ABCL |
|---|---|---|
| Price | $4.82 | $11.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $7.38 | ★ $18.00 |
| AVG Volume (30 Days) | 2.3M | ★ 3.2M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.83% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $30.23 | N/A |
| Revenue Next Year | $27.60 | $10.03 |
| P/E Ratio | $26.98 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $4.46 | $2.75 |
| 52 Week High | $7.18 | $14.98 |
| Indicator | TKC | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 45.51 |
| Support Level | $4.49 | $10.65 |
| Resistance Level | $5.22 | $13.21 |
| Average True Range (ATR) | 0.09 | 1.00 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 68.60 | 25.16 |
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Techfin, and Other. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.